MVA/S
A candidate COVID-19 viral vector vaccine.
General information
MVA/S is a candidate COVID-19 vaccine. It is based on a modified vaccinia Ankara (a highly attenuated strain of vaccinia virus) vector expressing membrane-anchored pre-fusion stabilized SARS-CoV-2 Spike protein (Routhu et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs
Spike protein Animal model Mixed substance |
Female BALB/c mice; male Indian rhesus macaques; infectious clone SARS-CoV-2; SARS-CoV-2 strain 2019-nCoV/USA_WA1/2020 | 22.55 | The vaccine elicited potent anti-SARS-CoV-2 neutralizing antibody and T cell responses in mice and macaques. IFNγ+ CD8 T cell response was dominant in macaques and the immunization protected their lungs in a SARS-CoV-2 challenge. An analysis of macaque bronchoalveolar lavage cells showed decreased inflammatory response in vaccinated animals compared to a non-vaccinated control. |
Feb/03/2021 |
AI-suggested references
| Link | Publication date |
|---|---|
|
A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 delta infection
|
Feb/05/2020 |
